Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM.

Elizabeth C. Matheson¹, Huw Thomas¹, Marian Case¹, Helen Blair¹, Rosanna K. Jackson¹, DMasic¹, Gareth Veal¹, Chris Halsey², David R Newell¹, Josef Vormoor¹,³ and Julie A.E Irving¹

1. Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
2. Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
3. Great North Children’s Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

Corresponding author: Dr Julie Irving, Northern Institute for Cancer Research, Herschel building, Newcastle upon Tyne, Tyne and Wear, UK, NE2 4HH. Tel. 0044-191-208-2234. Fax. 0044-191-208-4301. Email. j.a.e.irving@ncl.ac.uk.

Key words: glucocorticoids, MEK inhibitor, childhood acute lymphoblastic leukaemia, RAS signalling.

Running Title: Glucocorticoids and selumetinib in RAS pathway mutated ALL

Word count: abstract 203, main text 3614
Abstract

New drugs are needed for relapsed acute lymphoblastic leukemia and preclinical evaluation of the MEK inhibitor, selumetinib, has shown excellent activity in those with RAS pathway mutations. The proapoptotic protein, BIM is pivotal in the induction of cell death by both selumetinib and glucocorticoids, suggesting the potential for synergy. Thus, combination indices for dexamethasone and selumetinib were determined in RAS pathway mutated acute lymphoblastic leukemia primagraft cells \textit{in vitro} and were indicative of strong synergism (CI <0.2; n=5). Associated pharmacodynamic assays were consistent with the hypothesis that the drug combination enhanced BIM upregulation over single drug alone. Dosing of dexamethasone and selumetinib singly, and in combination in mice engrafted with primary derived RAS pathway mutated leukemia cells, resulted in a marked reduction in spleen size which was significantly greater with the drug combination. Assessment of the central nervous system leukaemia burden showed a significant reduction in drug treated mice, with no detectable leukemia in those treated with the drug combination. These data suggest that a selumetinib-dexamethasone combination may be highly effective in RAS pathway mutated acute lymphoblastic leukemia and an international phase I/II clinical trial of dexamethasone and selumetinib (Seludex trial) is underway for children with multiple relapsed/refractory disease.
Introduction

Progress in the treatment of childhood acute lymphoblastic leukaemia has been exceptional and using contemporary regimens, sustained remission is achievable in almost 90% of children \(^1\)\(^-\)\(^2\). However, the outcome of children who relapse is much poorer and remains a frequent cause of death in children with cancer \(^3\)\(^-\)\(^5\). Since further intensification with traditional agents is often associated with significant toxicity and limited success, new therapies are clearly needed. One promising avenue that may deliver novel drugs comes from our previous work showing that mutation in genes which activate the Ras/Raf/Mek/Erk pathway such as \(NRAS\), \(KRAS\), \(FLT3\), and \(PTPN11\) are highly prevalent in relapsed ALL and importantly, mutated ALL cells are differentially sensitive to the MEK inhibitor, selumetinib (AZD6244, ARRY-142886)\(^6\)\(^-\)\(^8\). In contrast, RAS pathway wildtype ALL cells were insensitive to MEK inhibition, both \textit{in vitro} and \textit{in vivo}\(^6\). In the \textit{IBFMREZ2002} clinical trial for relapsed ALL, RAS pathway mutations were associated with high risk features such as early relapse, central nervous system (CNS) disease and chemo-resistance and a poorer overall survival was seen in patients with \(KRAS\) mutations \(^6\). In the \textit{UKALLR3} trial, a poorer survival was seen in children with \(NRAS\) mutations \(^7\). Thus, this genetic subtype of relapsed ALL clearly warrants exploratory therapies.

The Ras/Raf/Mek/Erk cascade regulates diverse cellular functions, including cell proliferation, survival, differentiation, angiogenesis and migration and is deregulated in numerous cancers, including ALL \(^9\)\(^-\)\(^13\). Classic activation is initiated by ligand binding to receptor tyrosine kinases at the cell surface and via Ras, then Raf activates MEK1/2 which has restricted substrate specify for extracellular signal–regulated kinase 1 and 2 (Erk). ERK is a potent kinase with over 200 nuclear and cytoplasmic substrates including transcription
factors such as the ETS family and proteins involved in the apoptotic machinery, such as the proapoptotic BIM. Phosphorylation of the predominant form of BIM (BIM_{EL}) by ERK1/2, targets it for ubiquitination and proteasomal degradation and may also directly hinder its interactions with Bax^{14,15} and selumetinib-induced apoptosis is associated with BIM induction.\textsuperscript{16}

Relapsed ALL is generally more drug resistant than newly diagnosed disease and despite the use of more intensive chemotherapeutic regimens at ALL relapse, there are lower rates of complete remission and end of induction MRD negativity\textsuperscript{2,3}. Assessment of \textit{in vitro} drug sensitivity of primary ALL samples have shown that blasts at relapse are significantly more resistant to many of the drugs used in upfront treatment protocols, with the highest level of drug resistance seen to glucocorticoids (GC)\textsuperscript{17,18}. GC, such as dexamethasone, are pivotal agents in the treatment of all lymphoid malignancies due to their ability to specifically induce apoptosis in developing lymphocytes and induction of pro-apoptotic BIM is key to this effect\textsuperscript{19}. Thus, BIM is a common effector in both selumetinib and dexamethasone induced apoptosis, suggesting the potential for synergy. In addition, GC resistance in ALL has been associated with enhanced activation of the pathway and its inhibition has led to GC re-sensitisation\textsuperscript{20-22}. These effects may be more pronounced in the context of RAS pathway mutated ALL, therefore, we have preclinically evaluated the combination of dexamethasone and selumetinib \textit{in vitro} and in an orthotopic mouse model engrafted with primary-derived ALL cells and shown pronounced drug synergism in RAS pathway mutated ALL. These data suggest that this drug combination may be highly effective in this significant subgroup of patients and has led to the Seludex trial, an international Phase I/II expansion study for the treatment of relapsed/refractory RAS pathway mutated ALL.
Methods

Additional methods are found in the supplementary material.

Compounds and formulation

Selumetinib was kindly provided by AstraZeneca (Cheshire, UK) and for the in vitro studies, was dissolved in DMSO to a concentration of 100mM and stored in single use aliquots at -20°C. Dexamethasone was purchased from Sigma-Aldrich (Dorset, UK), dissolved in ethanol at 20mM and stored at -20°C. For in vivo studies, selumetinib was prepared as a suspension in 0.5% hydroxypropyl methylcellulose + 0.1% polysorbate 80.

Patient Samples

Primagrafts were generated in NOD SCID γ null (NSG) mice using ALL cells from bone marrow samples of children presenting or relapsing with ALL and accessed through the Newcastle Haematology Biobank, after appropriate consent (reference numbers 2002/111 and 07/H0906). Clinical details of the patients are given in Table 1. Mutational screening for RAS pathway mutations and assessment of pathway activation by western blotting of p-ERK was performed as previously described 8,23.

In vitro drug sensitivity and synergy

Freshly harvested primagraft cells were suspended in RPMI1640 with 15% fetal bovine serum and plated out in triplicate at a density of 5x10^5 cells/100μl/well into 96-well plates and treated with a range of dexamethasone (0.1nM to 10μM) or selumetinib concentrations (1nM to 100μM). After 96 hours, cytotoxicity was assessed using the CellTiter 96 Aqueous One kit.
(Promega, Southampton, UK). The results were averaged and expressed as a percentage of the control vehicle. Survival curves were plotted and growth inhibitory (GI50) values calculated using GraphPad Prism software (GraphPad software Inc., San Diego, CA, USA). Drug combination experiments were analysed for synergistic, additive, or antagonistic effects using the combination index method developed by Chou and Talalay. Briefly, primagraft cells were treated with fixed dose ratios based on the GI50 values of each drug (x0.25, x0.5, x1, x2 and x4) and evaluated by median effect analysis using CalcuSyn software (Cambridge, UK). The dose-effect curve for each drug alone is determined using the median-effect principle and is compared to the effect achieved with a combination of the two drugs to derive a combination index (CI) value.

**Pharmacokinetic analyses**

Plasma pharmacokinetics of selumetinib and dexamethasone were determined using non-compartmental analysis in female CD1 mice after oral dosing. Plasma concentrations of both drugs were measured by LCMS (API4000 LCMS/MS, Applied Biosystems, California, USA), attached to a Perkin Elmer chromatography system (Perkin Elmer Ltd, Beckonsfield, UK) and calibrated using standards prepared in blank mouse plasma. In both cases separation was performed using a Gemini 3µ C18 110A column (50x3mm) fitted with a 4x2mm C18 cartridge (Phenomenex, Macclesfield, UK).

**In vivo experiments**

All experiments were performed under the UK home Office NCL- PLL60/4552. Drug efficacy studies were performed as previously described. Briefly, primagraft cells were
injected intramuscularly and mice were monitored for engraftment every 3-4 weeks by tail
vein bleed. Blood was red cell lysed and analysed by flow cytometry on a BD FACSCanto II,
using anti human CD10, CD34 and CD19 and anti-mouse CD45 antibodies. Human
leukaemia cells were gated and expressed as a % of the total number of nucleated cells. Once
the level of human leukaemia cells reached >1% of total cells, mice were randomised into
control vehicle (0.5% hydroxypropyl methylcellulose + 0.1% polysorbate 80) and drug
treatment groups (6 mice per group) were dosed with dexamethasone, selumetinib or both, by
oral gavage. Selumetinib was dosed at 25mg/kg BID, while the dexamethasone dosing varied
in each study. Tumour burden was monitored weekly by flow cytometry. Pharmacodynamic
studies were performed in highly engrafted mice which were dosed for 72 hours. Spleens
were removed following euthanasia and assessed by flow cytometry to confirm an
engraftment of >85%. Cells were lysed and analysed by western blotting for levels of p-ERK,
ERK2, BIM, MCL1 and α-Tubulin, as described above.
Results

Selumetinib and dexamethasone show synergy *in vitro* in RAS pathway mutated ALL and is associated with enhanced induction of BIM.

To investigate possible synergism, the R3F9 cell line and primagraft ALL cells, with and without Ras pathway mutations (n=8) were treated with dexamethasone, selumetinib and the drug combination at 0.25x, 0.5x, 1x, 2x and 4x their respective GI50 concentrations and viability data evaluated by median effect analysis. CI for all RAS pathway samples were indicative of strong synergy with a mean of 0.1 (range, 0.02-0.15) (Figure 1A, B and Supplementary Figure 1). Synergism was not observed in ALL primagraft cells without RAS pathway activation, CI >1.2. Mechanistic assessments were performed with GI50 concentration of both drugs for 24 hours. As expected, ALL cells treated with selumetinib resulted in almost complete inhibition of ERK phosphorylation and downregulation of MCL1 levels. Dexamethasone treatment also downregulated pERK levels. Treatment with dexamethasone or selumetinib was associated with increased levels of BIM which was further enhanced with the drug combination. A representative western blot and a histogram of the combined densitometry values (n=4 PDX) are shown in Figures 1C and Supplementary Figure 2A. The apoptotic marker, cleaved PARP was enhanced with the drug combination in some, but not all PDX samples, at this time point (Supplementary Figure 2B). While the loss in cell viability in non-dividing PDX ALL cells must be due to increased cell death, we also showed for the NRAS mutated R3F9 cell line, enhanced apoptosis with the drug combination (Supplementary Figures 2 C and D) and BIM knockdown reduced the effect (Supplementary Figures 2E and F). There were similar levels of induction of the GR target gene, GILZ in both dexamethasone and drug combination treated cells suggesting that enhanced GR transcriptional activity is not a component of the synergism (supplementary Figure 3). Synergism between selumetinib and other drugs for example, gemcitabine, is highly schedule
dependent and sequential rather than simultaneous dosing appears optimal \(^{25}\). Thus, we assessed synergism in primagraft ALL cells dosed simultaneously or with only selumetinib or dexamethasone for 24 hours followed by both drugs for an additional 72 hours, prior to cell viability assessments. We saw similar synergism across all experimental parameters (Figure 1D) and thus we selected simultaneous drug administration in subsequent in vivo studies.

**Pharmacokinetic studies define clinically relevant oral dose and exclude drug-drug interactions**

To determine the optimal oral dose of dexamethasone that will achieve clinically relevant serum levels, pharmacokinetic studies were performed in CD1 mice. Mice (n=27) were dosed with 0.5, 1 and 5mg/kg dexamethasone by oral gavage and blood samples taken at 15min, 30min, 1hr, 3hr, 6hr and 24hr and serum dexamethasone levels analysed (Supplementary Figure 4A). A Tmax of 60 minutes was observed, with Cmax values of 48.9, 94.7 and 766.5 ng/ml following 0.5, 1 and 5mg/kg doses, respectively. Given the reported Cmax average of 40-90 ng/ml in recent UK and American ALL trials, 1mg/kg was deemed the most appropriate dose level \(^{26, 27}\).

Dexamethasone can induce cytochrome P450 forms, including CYP3A4, the principal isoform responsible for selumetinib oxidative metabolism, therefore we performed selumetinib pharmacokinetic analyses, alone (25mg/kg) and after co-administration of 1mg/kg dexamethasone (Supplementary Figures 4B and C). A Tmax of 60 minutes was observed, with Cmax values for selumetinib of 4.74ug/ml compared to 5.49 ug/ml, respectively (p>0.05, student t test). Other parameters were also similar (Supplementary Figure 4C), indicative of no drug-drug interaction (p>0.05 for all).
Selumetinib and dexamethasone show synergy in vivo and clear CNS disease

The drug combination was evaluated in vivo and compared to single drug and control vehicle in primagrafts derived from diagnostic ALL (NRAS Q61R and KRAS G12D) and a relapse (KRAS G13D). Scheduling and dosing was by oral gavage and is shown in Figure 2 A-G. Due to significant weight loss (>20%) associated with dexamethasone, dosing could not be prolonged, even when the dose was lowered from 1mg/kg bid to 0.25mg/kg sid. There was no additional toxicity observed in mice given the drug combination. Nevertheless, at the end of the dosing period, there was a significant reduction in spleen size with selumetinib and dexamethasone alone but was statistically lower in mice given the drug combination, with spleen weights approaching those of healthy mice (combined data are shown in Figure 2G) (p<0.001). In addition, brains were assessed for the depth of leukaemia infiltration in the leptomeninges. For mice engrafted with L897 and L779 primagraft cells, there was a significant reduction in leukaemic infiltration in drug treated mice, with a mean and SD of 66.3µ+/- 100.6 for CV, compared to 3.1µ +/- 12.5 for dexamethasone and 5.37µ +/- 21.475 for selumetinib (Supplementary Figure 5A). Mice treated with the drug combination showed no leukaemic infiltration (p<0.05 for all by student t test). For L779, there was demonstrable CNS disease once peripheral ALL exceeded 1% i.e. pre-dosing (Supplementary Figure 5B). Clearance of CNS disease in mice engrafted with L829R cells was unevaluable due to minimal CNS leukaemia in both CV and drug treated mice. Pharmacodynamic assessment of engrafted spleens after short term dosing were consistent with observations in vitro; inhibition of ERK phosphorylation and lower MCL1 levels associated with selumetinib dosing, similar induction of GILZ with dexamethasone dosing, and modest enhancement of BIM levels with the drug combination (Figure 3A-D). Annexin V binding in circulating ALL cells, as detected by multi-parameter flow cytometry, increased in all drug treated mice and was highest for the drug combination at both 24 hours and 48 hours (Figure 3E).
Discussion

Selumetinib is a potent, selective, allosteric inhibitor of MEK1/2 with demonstrated anti-tumour activity and a favourable toxicity profile. It has progressed to phase III clinical trial for several types of adult solid cancers28-30. In the paediatric setting, selumetinib has recently undergone phase I clinic testing as a monotherapy in children with \textit{BRAF}-driven recurrent/refractory paediatric low grade glioma which defined a maximum tolerated dose of 25 mg/m$^2$/dose BID\textsuperscript{31}. Sustained responses (1 complete, 7 partial) were observed in some children and selumetinib was well tolerated, with the most common toxicity being rash. In addition, a phase I trial of selumetinib in children with neurofibromatosis type 1 and inoperable plexiform neurofibromas, showed partial responses in 17 of 24 children (71\%) and reported no excess toxicity\textsuperscript{32}.

While we have previously shown single agent preclinical activity in ALL, selumetinib like other MEKi, is likely to show maximal therapeutic benefit in combination. Therefore, in phase III clinical trials for advanced non-small-cell lung cancer and uveal melanoma, selumetinib has been evaluated in combination with docetaxel and dacarbazine, respectively\textsuperscript{33}. In this current study, we show significant synergy of selumetinib with the synthetic glucocorticoid dexamethasone \textit{in vitro} and in an orthotopic mouse model engrafted with RAS pathway activated primary-derived ALL cells. Importantly, we demonstrate this across a range of cytogenetic subgroups, including high hyperdiploidy, B-other, t(17;19) and t(1;19). Pharmacokinetic data shows clinically relevant drug levels and optimal scheduling and \textit{in vivo} pharmacodynamic analyses confirmed impact on drug targets and apoptosis. Mechanistically, the synergism was associated with enhanced induction of the proapoptotic, BIM and decreases in the anti-apoptotic BH3 only protein MCL1. BIM is a BH3 only protein
that binds to anti-apoptotic BCL2 family members, including MCL1 and BCL2, to liberate and directly activate bax and bak which then elicit caspase dependent apoptosis. BIM is an effector protein in both GC and MEK inhibitor response and reducing pERK activity enhances BIM levels as well as decreasing MCL1 protein levels by increasing its turnover. Therefore, we propose that the drug combination enables BIM to more completely inhibit anti-apoptotic BH3 only proteins and directly activate BAX and BAK. Others have reported a direct effect of MEK inhibition on GR transcriptional activity which may also be contribute to the synergism, but this did not appear significant in our experiments at the time point chosen. Epigenetic regulation of the BIM locus due to acetylation has been described in a subgroup of GC resistant ALLs and is associated with BIM under expression. Such individuals may be expected to have a suboptimal response to the selumetinib/dexamethasone drug combination. However, the incidence of acetylated BIM in the relapsed setting and in the context of RAS pathway mutations has not been described to date. Our synergism data are supported by a study from Jones et al., who used an integrated approach to understand GC resistance and relapse and identified MAPK pathways as a contributory factor. In this study, knockdown of MEK2 or MEK inhibition enhanced response not only to GC but to other chemotherapeutics and was not dependent on the presence of RAS pathway mutations, suggestive of activation of the pathway through alternative routes. We have previously shown excellent correlation between pERK activation and the presence of RAS pathway mutations, although we too noted some rare exceptions which in our study were in part explained by the presence of chromosomal translocations, including Ph+ and 11q23.

Drug synergies have also been shown for MEK inhibitors with both traditional chemotherapeutics such as gemcitabine and targeted agents including PI3K/AKT inhibitors.
36, 37 and the BCL-XL inhibitor, Navitoclax (ABT263)38. Inhibiting the other effector pathways of RAS is clearly a rational strategy, however, while we have observed synergism of MEK and AKT inhibition in RAS pathway mutated ALL in vitro, the synergism was considerably weaker than that observed with dexamethasone (unpublished observations). In solid cancers, increased levels of BIM protein are also observed with MEK inhibition, but is inactive due to sequestration by high levels of BCL-XL. In the presence of Navitoclax, BIM is released, triggering an apoptotic response 38.

We have previously reported a reduction of CNS leukaemia in selumetinib treated mice and now confirm this in additional primagraft samples and show complete absence of leukaemic infiltrate in the leptomeninges of mice treated with the selumetinib/dexamethasone drug combination 6. The identification of CNS disease in mice with similar levels of ALL engraftment prior to drug dosing, suggests that the drug combination completely eradicated the leukaemia in situ. This is a highly significant finding given the association of RAS pathway mutations and CNS disease at relapse that we previously reported in the IBFMREZ2002 clinical trial and the fact that in contemporary regimens, the proportion of CNS relapses is increasing39.

A key question, relevant to MEKi therapy, is whether Ras pathway mutations are initiating events in ALL or secondary, cooperating genetic events and there is evidence for both (reviewed in 13). However, for targeted therapies to be successful, the target is ideally present on all tumour cells and we and others have reported that mutations can be subclonal, particularly at diagnosis, and can be gained or lost at relapse6,40-42. Importantly, we have also shown that mutations at relapse are in the major ALL clone, are often selected from a
minor subclone at diagnosis and that apparent ‘loss’ of a Ras pathway mutation can be ‘replacement’ of one for another \(^8,43,6\). This suggests a dependence on the pathway that can be exploited by MEK inhibition and as we show here, is enhanced with dexamethasone co-exposure.

Based on these promising data, an international phase I/II clinical trial of oral dexamethasone and selumetinib (Seludex) is underway in RAS pathway mutated, multiple relapse/refractory ALL. A parallel, national study in adult disease at first relapse is also ongoing, since the prevalence of RAS pathway mutations and association with poor prognosis has also been noted \(^44\). One relevant observation from selumetinib and other Mek inhibitor trials is that the most common toxicity is inflammatory rash. In severe cases, the recommended treatment is oral glucocorticoids and no adverse effects of drug co-administration have been reported \(^45\). Thus, if efficacy is seen in the proposed clinical trials, selumetinib and other Mek inhibitors may be a much needed novel therapy for a substantial number of children with high risk, relapsed disease. There may also be a role for the drug combination in the upfront treatment of RAS-driven, high risk ALL, to avert relapse.
Acknowledgements: The authors gratefully acknowledge Cancer Research UK (project grant to JAEI, HN and JV, number 18780), Bloodwise (previously known as the Leukaemia and Lymphoma Research Fund, project grant to JAEI, number 11007), the North of England Children’s Cancer Research Fund and the Newcastle Haematology Biobank for ALL samples. We are grateful to AstraZeneca for their kind donation of selumetinib. CH is funded by Chief Scientist Office (ETM/374). We thank Clare Orange and Lynn Stevenson, University of Glasgow and Think Pink, Scotland for help with histology and slide scanning.

Authorship: Contribution: JAEI was principal investigator and conceived and gained funding for the study, with input from HN, JV and LM. All authors designed, performed research and analysed and/or interpreted data. JI and LM drafted the article and all authors critically appraised and approved the final version.

Conflict of interest disclosure: The authors declare no competing financial interests.
References


33. Trials.gov C. Clinical Trials.gov.
34. Domin A, Vrana JA, Gregory MA, Hann SR, Craig RW. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene. 2004;23(31):301-315.
Table 1. Clinical features of patients and characterisation of PDX.

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Sex</th>
<th>Age at Diagnosis (years)</th>
<th>Cytogenetics</th>
<th>End of Induction MRD</th>
<th>Ras pathway mutation</th>
<th>Clonality</th>
<th>pERK</th>
</tr>
</thead>
<tbody>
<tr>
<td>L779</td>
<td>M</td>
<td>5.5</td>
<td>High Hyperdiploid</td>
<td>Intermediate</td>
<td>NRAS (Q61R)</td>
<td>Clonal</td>
<td>Positive</td>
</tr>
<tr>
<td>L897&lt;sup&gt;a&lt;/sup&gt;</td>
<td>M</td>
<td>16.8</td>
<td>B other</td>
<td>High risk</td>
<td>KRAS (G12D)</td>
<td>Clonal</td>
<td>Positive</td>
</tr>
<tr>
<td>L914</td>
<td>F</td>
<td>7.3</td>
<td>High Hyperdiploid</td>
<td>Low risk</td>
<td>CBL/FLT3 Large del/Δ836</td>
<td>Clonal</td>
<td>Positive</td>
</tr>
<tr>
<td>L829&lt;sup&gt;b&lt;/sup&gt; relapse</td>
<td>F</td>
<td>3.1</td>
<td>High Hyperdiploid</td>
<td>High risk</td>
<td>KRAS (G13D)</td>
<td>Clonal</td>
<td>Positive</td>
</tr>
<tr>
<td>L707&lt;sup&gt;c&lt;/sup&gt;</td>
<td>F</td>
<td>16.5</td>
<td>t(17;19)</td>
<td>High risk</td>
<td>KRAS (insertion)</td>
<td>Clonal</td>
<td>Positive</td>
</tr>
<tr>
<td>LX825</td>
<td>F</td>
<td>14.7</td>
<td>B other</td>
<td>High risk</td>
<td>Wildtype</td>
<td>N/A</td>
<td>Negative</td>
</tr>
<tr>
<td>L920</td>
<td>F</td>
<td>4.4</td>
<td>B other</td>
<td>Low risk</td>
<td>Wildtype</td>
<td>N/A</td>
<td>Negative</td>
</tr>
<tr>
<td>L848</td>
<td>M</td>
<td>2.5</td>
<td>t(12;21)</td>
<td>Low risk</td>
<td>Wildtype</td>
<td>N/A</td>
<td>Negative</td>
</tr>
</tbody>
</table>

<sup>a</sup> patient suffered on-treatment CNS relapse

<sup>b</sup>L829 at diagnosis was NRAS G12D

<sup>c</sup> patient relapsed with the same KRAS mutation

B-other group:-

L897 is negative by FISH for ETV6-RUNX1, BCR-ABL1, MLL and TCF3-PBX1/HLF

LX825 is negative by FISH for ETV6-RUNX1, BCR-ABL1, MLL, CRLF2, IKZF1, PAX5, IGH and PDGFRB
Figure Legends

Figure 1. Selumetinib and dexamethasone show synergy in vitro in RAS pathway mutated ALL and is associated with enhanced levels of BIM

Viability curves of Ras pathway mutant ALL cells (L829R) with individual drugs and the selumetinib/dexamethasone drug combination (A). Histogram of combination indices (CI) for the selumetinib/dexamethasone combination in wild type and Ras pathway mutant ALL cells; mutated genes are shown in brackets (B). Western analyses of ALL cells (L829R) treated with CV or GI50 values of selumetinib (10 µM) and dexamethasone (10 µM), singly and in combination (C). A representative median effect curve (data shown are from L897) after simultaneous drug dosing and with each drug added 24 hours prior to the partner drug, followed by a further 72 hours incubation (D).

Figure 2. Selumetinib and dexamethasone show synergy in vivo in RAS pathway mutated ALL

In vivo drug efficacy studies of single drug and combination in RAS pathway mutated ALL showing dose scheduling and peripheral blood monitoring before and during dosing and spleen weights at the end of dosing for L779-NRAS (A and B, respectively), L897-KRAS (C and D) and L829 relapse- KRAS (E and F). For L779, mice were dosed with selumetinib at 25mg/kg and dex at 1mg/kg twice daily and then once daily after a recovery period. For L897, selumetinib was 25mg/kg and dex at 0.5mg/kg (BID), with the dex being increased to 1mg/kg (SID) following a recovery period and for L829R, selumetinib was dosed at 25mg/kg (BID) and dex at 0.25mg/kg (SID). Mean and SD are shown for combined spleen weight data for all 3 efficacy experiments (G) (One way ANOVA with Tukeys multiple
comparison test, ***p <0.001, **** p<0.0001; n=17 for CV, n=17 for Sel, n=15 for Dex and n=14 for Sel and Dex treated mice).

**Figure 3. Pharmacodynamic analyses in ALL cells after drug dosing *in vivo*, supports *in vitro* data.**

Western analyses of spleen cells from mice engrafted with RAS pathway mutant ALL cells after 72 hours of dosing (A, L779; NRAS; 25mg/kg selumetinib and 1mg/kg dexamethasone bid and B, L897; KRAS; 25mg/kg selumetinib and 0.5mg/kg dexamethasone bid).

Histograms of densitometry from western analyses, showing mean +/-SEM (3-4 mice per treatment) (One way ANOVA with Tukeys multiple comparison test, * p<0.05, **p <0.01, (C). Relative expression of GILZ mRNA (mean and SEM) compared to CV as quantified by RQPCR expression in all 3 PDX experiments, again after 72 hours dosing (ANOVA as before **p<0.01; ns, not significant (D). Histograms of annexin V positive ALL cells (mean +/-SEM) determined by flow cytometric analyses of peripheral blood at 24 and 48 hours after dosing (2 mice per group)(E).